Jing Wu MD

PubMed

• Exploiting the therapeutic vulnerability of IDH-mutant gliomas with zotiraciclib.
  Ying Pang, Qi Li, Zach Sergi, Guangyang Yu, Olga Kim
  Iscience. 2025-04-18
• Therapy enhancing chromosome instability may be advantageous forgliomas.
  Nikolay V Goncharov, Ivan N Baklanov, Valeriia S Gulaia, Anastasiia P Shuliak, Daria V Lanskikh
  NAR Cancer. 2025-03-01
• The COVID-19 pandemic experience for patients with central nervous system tumors: Differences in patient-reported outcomes and practice recommendations.
  Amanda L King, Kayla N Roche, Elizabeth Vera, Valentina Pillai, Lily Polskin
  Neuro-Oncology Practice. 2025-02-01

Journal Articles

• Neoplastic Myelopathies  
  Wu J and Ranjan S, Neurology Continuum (Spinal Cord Disorders), 1/1/2018
• Contemporary Murine Models in Preclinical Astrocytoma Drug Development  
  McNeill RS, Vitucci M, Wu J, Miller CR, Neuro-Oncology, 1/1/2015

Books/Book Chapters

• Targeted Therapy for Solid Tumors and Hematologic Malignancies 
  Chapter: Targeted Therapy for Solid Tumors and Hematologic Malignancies 
  Page 73 - 93Wu J and Gilbert MREditors: Alfonso-Quintas-Cardama, DL Gibbons, V Cataldo.Nova Science Publishers, New York, NY2011
• Controversies in Neuro-Oncology 
  Chapter: Avastin Treatment for CNS Radiation Necrosis 
  Page 117 - 126Wu J and Levin VAEditors: TC Chen and MC Chamberlain.Bentham Books2010
• Controversies in Neuro-Oncology 
  Chapter: Controversies in Neuro-Oncology 
  Page 40 - 45Wu J and Gilbert MREditors: TC Chen and MC Chamberlain.Bentham Books2010

Lectures

• Phase I trial of TG02 plus dose-dense or metronomic temozolomide for recurrent anaplastic astrocytoma and glioblastoma in adults. 
  2019 ASCO Annual Meeting - 6/1/2019